Impact of thyroid hormone treatment on maternal pregnancy outcomes in women with subclinical hypothyroidism without TPOAb

Abstract

Abstract Purpose: To investigate the impact of thyroid hormone treatment (LT4) on maternal pregnancy outcomes in women with subclinical hypothyroidism (SCH) without thyroid peroxidase antibodies (TPOAb) positivity. Design/Methods: Single centre, cross-sectional study in 1460 women screened for TSH, free T4 and TPOAb at median 13 (11-17) weeks of gestation during the period 2013-2014. Exclusion criteria were twin- and assisted reproduction pregnancies, TPO positivity, overt hyperthyroidism, and treatment with LT4 before screening. The impact of LT4 on maternal pregnancy outcomes was investigated in a group of 53 women with SCH (TSH >3.74 mIU/L) in which LT4 was initiated at median 13 (10-22) weeks (treated group). The control group included 18 women with SCH (TSH >3.74 mIU/L; untreated group). The prevalence of pregnancy complications in these two groups was compared with that in a reference group of 1389 women (TSH £3.74 mIU/L and no TPOAb; REF group). Results: The prevalence of pre-eclampsia and gestational diabetes (GDM) was higher in the control group vs that in the REF group (16.7% vs 5.0% and 27.8% vs 18.9%; p=0.017 and p=0.016, respectively), but comparable in the LT4 treated SCH group vs the REF group (7.6% vs 5.0% and 22.6% vs 18.9%; p=0.918 and 0.676, respectively). The prevalence of iron-deficiency anaemia was lower in the LT4 treated vs the REF group (17.0% vs 32.5%; p=0.017). Conclusions: Pregnant women with SCH and without TPOAb positivity who were LT4 untreated had a higher prevalence of pre-eclampsia and GDM compared with euthyroid women, while this was not the case when SCH women were treated with LT4, even when it was initiated after the first trimester.